Abelacimab justifies its spin-out into the Blackstone-backed private biotech Anthos Therapeutics, and a big deal could follow.
Novo moves into amyloidosis not long after Intellia made a splash here.
After several cancer failures Celldex tries its hand at autoimmune disease, and the market likes it.
Big risers include Eli Lilly, Biogen, Moderna and Biontech.
The deal puts more support behind targeting folate receptor α, a long troubled target, with antibody-drug conjugates.
The failure of gosuranemab could bode ill for Abbvie’s ABBV-8E12 in particular.
Casirivimab plus imdevimab could at last add a hospitalised Covid-19 patient treatment string to their bow.
But AZD7442 still has two more bites at the cherry.
Acumen is the latest player to take aim at amyloid, but competition is fierce.